The Pathophysiology of Hidradenitis Suppurativa

Iltefat Hamzavi, MD, describes the pathophysiology of hidradenitis suppurativa and associated comorbidities that are commonly seen in patients.

EP: 1.Signs and Symptoms of Hidradenitis Suppurativa (HS)

EP: 2.Epidemiology and Impact of Hidradenitis Suppurativa

Now Viewing

EP: 3.The Pathophysiology of Hidradenitis Suppurativa

EP: 4.Differential Diagnosis When Considering Hidradenitis Suppurativa in a Patient

EP: 5.Overview of the Hurley Staging System for Hidradenitis Suppurativa

EP: 6.Comorbidities and Coordinating Care Between Specialists in Hidradenitis Suppurativa

EP: 7.Hidradenitis Suppurativa: Addressing the Psychosocial Impact and Hospitalization Rate

EP: 8.The Impact of Hidradenitis Suppurativa on Families

EP: 9.Hidradenitis Suppurativa (HS): Staging Considerations and Unmet Needs

EP: 10.The Role of Treatment Guidelines for HS

EP: 11.Biologic Therapies for Hidradenitis Suppurativa

EP: 12.Recent Data on Bimekizumab for Hidradenitis Suppurativa

EP: 13.Ongoing Research in Hidradenitis Suppurativa

EP: 14.Managing Pain in Patients with Hidradenitis Suppurativa

EP: 15.The Role of Surgery in Hidradenitis Suppurativa

EP: 16.Optimizing Multidisciplinary Care of Patients with Hidradenitis Suppurativa

Video content above is prompted by the following question(s):

• What is the pathophysiology of hidradenitis suppurativa (HS) and are there any risk factors for being affected by this disease?

Related Videos

Related Content

Advertisement

January 14th 2025

Eczema Incidence Associated With Dietary Calcium Intake

Cameron Santoro

Increased eczema risks in certain populations were associated with moderately high calcium intake, although pregnant women were found to potentially benefit from higher calcium consumption.

January 12th 2025

Hidradenitis Suppurativa: Advancing Treatment With Biologics

Cameron Santoro

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for patients, especially those who experience loss of response.

January 11th 2025

Student-Run Clinics Expand Access to Dermatology Care

Cameron Santoro

For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a potentially cost-effective access point to dermatological care.

January 9th 2025

Vitiligo Linked to Higher Cardiovascular Disease Risk

Cameron Santoro

Vitiligo, a skin condition causing depigmentation, may significantly increase the risk of serious cardiovascular events.

December 16th 2024

FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis

Brooke McCormick

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

November 21st 2024

Collaborating for Cancer Care Equity: Community and Academic Insights

Maggie L. Shaw

Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.

Related Content

Advertisement

January 14th 2025

Eczema Incidence Associated With Dietary Calcium Intake

Cameron Santoro

Increased eczema risks in certain populations were associated with moderately high calcium intake, although pregnant women were found to potentially benefit from higher calcium consumption.

January 12th 2025

Hidradenitis Suppurativa: Advancing Treatment With Biologics

Cameron Santoro

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for patients, especially those who experience loss of response.

January 11th 2025

Student-Run Clinics Expand Access to Dermatology Care

Cameron Santoro

For diverse patient populations who are historically marginalized within health care, student-run clinics may offer a potentially cost-effective access point to dermatological care.

January 9th 2025

Vitiligo Linked to Higher Cardiovascular Disease Risk

Cameron Santoro

Vitiligo, a skin condition causing depigmentation, may significantly increase the risk of serious cardiovascular events.

December 16th 2024

FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis

Brooke McCormick

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis.

November 21st 2024

Collaborating for Cancer Care Equity: Community and Academic Insights

Maggie L. Shaw

Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.